Last reviewed · How we verify

YAZ (SH T00186, BAY86-5300)

Bayer · Phase 3 active Small molecule

YAZ (SH T00186, BAY86-5300) is a Small molecule drug developed by Bayer. It is currently in Phase 3 development.

YAZ is a combination oral contraceptive that contains drospirenone and ethinyl estradiol, which work to prevent ovulation and thicken cervical mucus to prevent sperm from reaching the egg.

At a glance

Generic nameYAZ (SH T00186, BAY86-5300)
SponsorBayer
ModalitySmall molecule
PhasePhase 3

Mechanism of action

Drospirenone, a progestin, has anti-androgenic and anti-mineralocorticoid effects, which contribute to its contraceptive efficacy. Ethinyl estradiol, an estrogen, helps to regulate the menstrual cycle and prevent ovulation.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about YAZ (SH T00186, BAY86-5300)

What is YAZ (SH T00186, BAY86-5300)?

YAZ (SH T00186, BAY86-5300) is a Small molecule drug developed by Bayer.

How does YAZ (SH T00186, BAY86-5300) work?

YAZ is a combination oral contraceptive that contains drospirenone and ethinyl estradiol, which work to prevent ovulation and thicken cervical mucus to prevent sperm from reaching the egg.

Who makes YAZ (SH T00186, BAY86-5300)?

YAZ (SH T00186, BAY86-5300) is developed by Bayer (see full Bayer pipeline at /company/bayer).

What development phase is YAZ (SH T00186, BAY86-5300) in?

YAZ (SH T00186, BAY86-5300) is in Phase 3.

Related